Osteoarthritis

Efficacy and Safety of Tramadol for Knee or Hip Osteoarthritis: A Systematic Review and Network Meta‐Analysis of Randomized Controlled Trials

Arthritis Care Res (Hoboken)Published Systematic review and network meta-analysis of randomised controlled trials

Authors' conclusion

Only tramadol 300 mg/day showed minimal improvement in pain and function but with increasing AEs compared with placebo.

Study context

Population
Randomized Controlled Trials (RCTs) in knee or hip Osteoarthritis (OA); PubMed, Embase, Cochrane Library and Web of Science searched to May 2020
Participants
3,611 participants6 RCTs
Comparison
Tramadol 100, 200 and 300 mg/day vs placebo
Outcome
Efficacy: pain and function
Follow-up
At or near 12 weeks
Methodological detailsBayesian network meta-analysis
  • Bayesian network meta-analysis

Pooled result

As reported in the abstract

Pain relief
Each group vs placeboSMD (95% CI)
Tramadol 100 mg/day
−0.16(−0.34 to 0.00)
Tramadol 200 mg/day
−0.21(−0.37 to −0.06)
Tramadol 300 mg/day
−0.30(−0.48 to −0.14)

Further pooled results

OutcomeSMD (95% CI)
Functional improvement · at or near 12 weeksTramadol 300 mg/dayvs Placebo−0.24 (−0.47 to −0.03)

Functional improvement · at or near 12 weeks

Only tramadol 300 mg/day was better than placebo in functional improvement

Safety

OutcomeRR (95% CrI)
Gastrointestinal AEsTramadol 100 mg/dayvs PlaceboCrI2.29 (1.22–4.25)
Gastrointestinal AEsTramadol 200 mg/dayvs PlaceboCrI4.35 (2.31–8.01)
Gastrointestinal AEsTramadol 300 mg/dayvs PlaceboCrI6.02 (3.22–11.1)

CNS adverse events (AEs) and withdrawals

Tramadol 100-300 mg/day showed a higher risk of CNS AEs and withdrawals

Cardiovascular AEs

Risk of cardiovascular AEs remained unclear

Original publication

Efficacy and Safety of Tramadol for Knee or Hip Osteoarthritis: A Systematic Review and Network Meta‐Analysis of Randomized Controlled Trials. Arthritis Care Res (Hoboken). Published 23 August 2022. doi:10.1002/acr.24750

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.